Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations

Human Pathology

Volumn 33, Issue 5, 2002, Pages 484-495

  Heinrich, Michael C ^a,b,c,d,e   Rubin, Brian P ^a,b,c,d,e   Longley, B Jack ^a,b,c,d,e   Fletcher, Jonathan A ^a,b,c,d,e  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^c College of Physicians and Surgeons of Columbia University ^*  (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Cytogenetics; Gastrointestinal neoplasm; KIT; Mutation; Oncogenic; Receptor tyrosine kinase; Sarcoma

Indexed keywords

PROTEIN TYROSINE KINASE; STEM CELL FACTOR;

APOPTOSIS; CANCER GENETICS; CANCER GRADING; CARCINOGENESIS; CELL ADHESION; CELL PROLIFERATION; CHEMOTAXIS; CHROMOSOME 14; CHROMOSOME 22; CHROMOSOME DELETION; CONFERENCE PAPER; CYTOGENETICS; DRUG RESPONSE; GASTROINTESTINAL TUMOR; HISTOPATHOLOGY; HUMAN; POINT MUTATION; PROTEIN PHOSPHORYLATION;

EID: 0036303804     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1053/hupa.2002.124124     Document Type: Article

References (68)

1. c-kit protein, a transmembrane kinase: Identification in tissues and characterization
2. Activation of the human c-kit product by ligand-induced dimerization mediates circular actin reorganization and chemotaxis
3. From white spots to stem cells: The role of the KIT receptor in mammalian development
4. Structure-function analyses of the KIT receptor for the Steel factor
5. Crystal structure of human stem cell factor: Implication for stem cell factor receptor dimerization and activation
6. Hereditary anemias of the mouse: A review for geneticists
7. Decreased production of mast cells in S1/S 1d anemic mice
8. W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity
9. Disturbed intestinal movement, bile reflux to the stomach, and deficiency of c-kit-expressing cells in Ws/Ws mutant rats
10. Developmental origin and KIT-dependent development of the interstitial cells of Cajal in the mammalian small intestine
11. Blockade of KIT signaling induces transdifferentiation of interstitial cells of Cajal to a smooth muscle phenotype
12. Disturbed pyloric motility in Ws/Ws mutant rats due to deficiency of c-kit-expressing interstitial cells of Cajal
13. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors
14. A novel gain-of-function mutation of c-kit gene in gastrointestinal stromal tumors
15. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors
16. Familial gastrointestinal stromal tumours with germline mutation of the KIT gene
17. Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors
18. Cause of familial and multiple gastrointestinal autonomic nerve tumors with hyperplasia of interstitial cells of Cajal is germline mutation of the c-kit gene
19. Familial gastrointestinal stromal tumor with hyperpigmentation: Association with a germline mutation of the c-kit gene
20. Germline mutation in the juxtamembrane domain of the kit gene in a family with gastrointestinal stromal tumors and urticaria pigmentosa
21. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product
22. Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P- 815 generated by a point mutation
23. Substitution of an aspartic acid results in constitutive activation of c-kit receptor tyrosine kinase in a rat tumor mast cell line RBL-2H3
24. Constitutive activation of c-kit in FMA 3 murine mastocytoma cells caused by deletion of seven amino acids at thejuxtamembrane domain
25. c-kit point mutation of extracellular domain in patients with myeloproliferative disorders
26. Activating c-kit gene mutations in human germ cell tumors
27. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis
28. KIT mutation portends poor prognosis in gastrointestinal stromal/smooth muscle tumors
29. Mutations of c-kit JM domain are found in a minority of human gastrointestinal stromal tumors
30. Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas
31. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors
32. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors
33. Inhibition of spontaneous receptor phosphorylation by residues in a putative alphahelix in the KIT intracellular juxtamembrane region
34. Classes of c-KIT activating mutations: Proposed mechanisms of action and implications for disease classification and therapy
35. The c-kit mutation causing human mastocytosis is resistant to STI-571 and other KIT kinase inhibitors: Kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations
36. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: Establishment of clonality in a human mast cell neoplasm
37. Indolinone derivatives inhibit constitutively activated KIT mutants and kill neoplastic mast cells
38. Structural basis for autoinhibition of the Ephb 2 receptor tyrosine kinase by the unphosphorylated juxtamembrane region
39. Clustering of activating mutations in c-KIT’s juxtamembrane coding region in canine mast cell neoplasms
40. Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors: A study of 200 cases
41. Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours
42. c-kit point mutation in patients with myeloproliferative disorders
43. c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia
44. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
45. Early signaling pathways activated by c-Kit in hematopoietic cells
46. Kit signal transduction
47. Oncogenic mutation in the Kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP- 1
48. Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant
49. Stat1 associates with c-kit and is activated in response to stem cell factor
50. Constitutively activated Stat3 protects fibroblasts from serum withdrawal and UV-induced apoptosis and antagonizes the proapoptotic effects of activated Stat 1
51. Requirement of phosphatidylinositol-3 kinase for activation of JNK/SAPKs by PDGF
52. The oncogenic TEL/PDGFR beta fusion protein induces cell death through JNK/SAPK pathway
53. c-kit receptor signaling through its phosphatidylinositide-3′-kinase-binding site and protein kinase C: Role in mast cell enhancement of degranulation, adhesion, and membrane ruffling
54. Activating mutations in the Met receptor overcome the requirement for autophosphorylation of tyrosines crucial for wild-type signaling
55. The receptor tyrosine kinase c-kit provides a critical signal for survival, expansion, and maturation of mouse natural killer cells
56. The leukaemic oncoproteins Bcr-Abl and Tel-Abl (ETV6/Abl) have altered substrate preferences and activate similar intracellular signalling pathways
57. A novel mechanism of cooperation between c-Kit and erythropoietin peceptor. Stem cell factor induces the expression of STAT5 and erythropoietin receptor, resulting in efficient proliferation and survival by erythropoietin
58. Signalling by the W/Kit receptor tyrosine kinase is negatively regulated in vivo by the protein tyrosine phosphatase Shp 1
59. SHP-1 binds and negatively modulates the c-Kit receptor by interaction with tyrosine 569 in the c-Kit juxtamembrane domain
60. Expression of isoforms of the human receptor tyrosine kinase c-kit in leukemic cell lines and acute myeloid leukemia
61. Isoforms of c-KIT differ in activation of signalling pathways and transformation of NIH 3T3 fibroblasts
62. The biology of stem cell factor and its receptor C-kit
63. Three possible cytogenetic subgroups of leiomyosarcoma
64. Recurrent chromosome aberrations in abdominal smooth muscle tumors
65. Chromosomal abnormalities in leiomyosarcomas
66. Two cases of low-grade gastric leiomyosarcoma with monosomy 14 as the only change
67. G-band analyses of a human intestinal leiomyosarcoma
68. DNA sequence copy number changes in gastrointestinal stromal tumors: Tumor progression and prognostic significance